Page 18 - Y. Vascular biology
P. 18

[Y. Vascular biology-10]



                    NF-kB-responsive microRNA-155 induces functional


               impairment of VSMCs by downregulating soluble guanylyl


                                                       cyclase



              Minsik Park¹, Wonjin Park¹, Suji Kim¹, Taesam Kim¹, Young-Guen Kwon², Young-Myeong Kim¹


             ¹Departments of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University,

         Chuncheon 24341, South Korea, ²Department of Biochemistry, College of Life Science and Biotechnology, Yonsei
                                            University, Seoul 03722, South Korea




        VSMCs play an important role in maintaining vascular function. Inflammation-mediated VSMC dysfunction leads to

        atherosclerotic intimal hyperplasia and preeclamptic hypertension. We analyzed the expression levels of miR-155 in
        cultured VSMCs, mouse vessels, and clinical specimens, and then assessed its role in VSMC function. Treatment with

        TNF-α  elevated  miR-155  biogenesis  in  cultured  VSMCs  and  vessel  segments,  which  was  prevented  by  NF-kB
        inhibition.  MiR-155  expression  was  also  increased  in  high  fat  diet-fed  ApoE-/-  mice  and  in  patients  with

        atherosclerosis  and  preeclampsia.  MiR-155  levels  were  inversely correlated  with sGCβ1 expression and NO-
        dependent cGMP production through targeting of the sGCβ1 transcript. TNF-α-induced miR-155 caused VSMC

        phenotypic  switching, as confirmed  by  the downregulation of  VSMC-specific  marker  genes,  suppression  of cell
        proliferation and migration, alterations in cell morphology, and NO-induced vasorelaxation. Moreover, TNF-α did

        not cause VSMC phenotypic modulation and limit NO-induced vasodilation in aortic vessels of miR-155-/- mice.
        These findings suggest that NF-kB-induced miR-155 impairs the VSMC contractile phenotype and NO-mediated

        vasorelaxation by downregulating sGCβ1 expression in atherosclerosis and preeclampsia.
   13   14   15   16   17   18   19   20   21   22